Sign In
Upcoming Event
Free Newsletter
David Ricks, chair and CEO of Eli Lilly announces his company's $3.5 billion investment in a new pharmaceutical manufacturing facility in the Lehigh Valley. PHOTO/PA CAST
Eli Lilly reporting strong fiscal performance
Stacy Wescoe//February 4, 2026//
On the heels of its announcement that it was investing $3.5 billion to bring a pharmaceutical manufacturing facility to Upper Macungie Township, Eli Lilly is reporting strong financials and predictions for continued growth in 2026.
“2025 was an important year for Lilly,” said David A. Ricks, Lilly’s chair and CEO. “We reached millions more patients—launching Inluriyo, expanding Mounjaro and Kisunla globally, and submitting orforglipron for approval. We expanded our manufacturing capacity, and through our U.S. government agreement, opened new access to obesity medicines. Entering our 150th year with a deep pipeline and platforms like LillyDirect, we’re positioned to reach more patients than ever and expand our global health impact.”
Ricks reported that revenue increased 43% in the fourth quarter of 2025 to $19.3 billion, driven by growth from its Moujarno and Zepbound products.
Revenue outside the U.S. increased 43% during the fourth quarter to $6.4 billion, driven by a 38% increase in volume and to a lesser extent a 4% favorable impact on foreign exchange rates.
For 2026 Ricks said the company is predicting a very strong year with between $80 to $83 billion in revenue with $33.50 to $35 in earnings per share.
Eli Lilly said earlier that it plans to begin construction on its Lehigh Valley facility this fall with a planned completion by 2031.
The Lehigh Valley facility is one of four new facilities the company is planning for the U.S.
